Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986279 is a zirconium-89-labeled monoclonal antibody-based PET imaging agent developed for targeting fucosyl-GM1 (fuc-GM1), a membrane glycolipid antigen expressed in small cell lung cancer (SCLC). BMS-986279 is a modified version of BMS-986012, designed for use as a radiotracer in imaging studies. Its main use is to non-invasively assess and visualize the expression of fuc-GM1 in tumor tissue using PET-CT, supporting the selection or evaluation of immunotherapy strategies that target this antigen. The radiotracer’s primary mechanism is high-affinity and selective binding to fuc-GM1, providing tumor localization through imaging rather than direct therapeutic intervention.[1][4][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BMS-986279.